Aladdin Healthcare Technologies SE

DB:NMI Stock Report

Market Cap: €269.3k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aladdin Healthcare Technologies Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Wade Menpes-Smith

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership14.8%
Management average tenureno data
Board average tenure4.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Wade Menpes-Smith's remuneration changed compared to Aladdin Healthcare Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2021n/an/a

€12k

Mar 31 2021n/an/a

-€610k

Dec 31 2020n/an/a

-€1m

Sep 30 2020n/an/a

-€2m

Jun 30 2020n/an/a

-€3m

Mar 31 2020n/an/a

-€3m

Dec 31 2019€137k€100k

-€3m

Sep 30 2019n/an/a

-€4m

Jun 30 2019n/an/a

-€4m

Mar 31 2019n/an/a

-€4m

Dec 31 2018€205k€170k

-€5m

Compensation vs Market: Insufficient data to establish whether Wade's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Insufficient data to compare Wade's compensation with company performance.


CEO

Wade Menpes-Smith

no data

Tenure

Mr. Wade Menpes-Smith serves as Chief Executive Officer, Managing Director & Chairman of the Board of Directors at Aladdin Healthcare Technologies SE (formerly known as Aladdin Blockchain Technologies Hold...


Board Members

NamePositionTenureCompensationOwnership
Wade Menpes-Smith
Chairman of the Boardno datano data14.8%
€ 39.9k
Bimal Shah
Deputy Chairman & COOno datano datano data
Hamish Badenoch
CFO & Director2.3yrsno datano data
David Rubinsztein
Member of Drug Discovery Advisory Board & Chief Scientific Advisor2.4yrsno datano data
Evandro Fang
Member of Early Diagnosis Advisory Board & Adviser of Early Stage Drug Discovery4.1yrsno datano data
Jon Storm-Mathisen
Member of Drug Advisory Board & Adviser of Neurological Research4.1yrsno datano data
Linda Bergersen
Member of Early Diagnosis Advisory Board & Adviser of Aging4.1yrsno datano data
Hilde Nilsen
Member of Early Diagnosis Advisory Board & Adviser of Biological Research4.1yrsno datano data
Henrik Schirmer
Member of Drug Advisory Board & Adviser of Cardiovascular4.1yrsno datano data
Guang Yang
Member of Drug Discovery Advisory Board & Adviser of Medical Imaging4.1yrsno datano data
Geir Selbæk
Member of Drug Discovery Advisory Board & Adviser of Biobank3.2yrsno datano data

4.1yrs

Average Tenure

Experienced Board: NMI's board of directors are considered experienced (4.1 years average tenure).